|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Triptolide Inhibits Cyclooxygenase-2 and Inducible Nitric Oxide Synthase Expression in Human Colon Cancer and Leukemia Cells显示文摘Triptolide ( TP ),繁体中文药,被报导了在在几人的肿瘤 celllines.This 研究的肿瘤的活动调查的自体免疫的疾病和施加的反的治疗有效在人的结肠癌房间( SW114 )的 TP 的反肿瘤效果 andmyelocytic 白血病( K562 ),并且阐明可能的分子的机制 involved.SW114 和 K562cells 与 TP ( 0,5,10,20 ,或 50 ng/ml )的不同剂量被对待。房间生存能力被 3- 估计[4,5-dimethylthiazol-2-yl ]-2,5-diphenyltetrazolium 溴化物(MTT ) 。结果证明 TP 以一种剂量依赖者方式禁止了两根肿瘤房间线的增长。为了推进,调查它的机制,产品前列腺素 E2 (PGE2 ) 和氮的氧化物(没有) 被连接酶的免疫吸着剂试金(ELISA ) 测量。我们的数据证明 TP 强烈禁止了生产没有并且有这些的 PGE2.Consistent 结果,表示可诱导合酶(i NOS ) 和 cyclooxygenase-2 (COX-2 ) 都不在 mRNA 水平和蛋白质表示水平两个都是起来调整的由即时 RT-PCR 并且西方的弄污出现。这些结果显示煽动性的因素 COX-2 和 i NOS 活动的抑制能涉及 TP 的 antitumormechanisms。 | Xiangmin TONG~# Shui’er ZHENG~# Jie JIN Lifen ZHU Yinjun LOU and Hangping YAO Institute of Hematologic Disease,Department of Hematology,First Affiliated Hospital,Medical School,Zhejiang University,Hangzhou 310003,China | 2007 | Acta Biochimica et Biophysica Sinica2007，39，2： | 12 |
| 2 | Salvage therapy with lenalidomide containing regimen for relapsed/refractory Castleman disease: a report of three cases显示文摘Castleman 疾病(CD ) 是有未知病原学的不平常的非同种细胞的 lymphoproliferative 混乱。没有标准治疗为 relapsed/refractory CD 病人被推荐,因此要求新奇试验性的途径的开发。我们有 multicentric CD (MCD ) 的三个成年病人的队被对待与对传统的化疗包含 lenalidomide 政体倔强(1025 mg lenalidomide perorally 在天管理了 121 在 28 天的周期) 作为第二 -- 到第四线的治疗。部分宽恕在第一个血浆房间 CD 病人被完成, relapsed 在自体同源的造血的干细胞移植以后的七个月然后没能对化疗的四个周期作出回应。organomegaly,部分宽恕与 CD 和 polyneuropathy 在第二个病人被获得 endocrinopathy, monoclonal gammopathy,和皮肤变化症候群。第三个案例与血小板计数的肋膜的流出和腹水和正规化的完全的消失显示出完全的宽恕。得出结论,令人鼓舞的临床的回答与基于 lenalidomide 的政体在三个病人的队被完成,不过,长期的功效尚待被遵守。我们在对待 MCD 建议这药的治疗学的潜力的进一步的调查。 | Xinping Zhou Juying Wei Yinjun Lou Gaixiang Xu Min Yang Hui Liu Liping Mao Hongyan Tong Jie Jin | 2017 | Frontiers of Medicine2017，11，2： | 6 |
| 3 | Efficacy and prognostic factors of imatinib plus CALLG2008 protocol in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia显示文摘一个 CALLG2008 协议被中国尖锐成淋巴细胞的白血病合作的组为成年尖锐成淋巴细胞的白血病(所有) 开发。我们回顾地与费城染色体(Ph ) 分析了 153 个最新诊断的成年病人积极加在 2009 和 2015 之间的 CALLG2008 政体注册进 imatinib (400 mg/d ) 的所有。中部的年龄是 40 年(范围, 1868 年) ,与 81 (52.3%) 男性。全面 hematologic 完全的宽恕(CR ) 率在正式就职以后是 96.7% 。与 24.2 个月的中部的后续,估计的 3 年的全面幸存(OS ) 和没有事件的幸存(EFS ) 评价是 49.5%(95% 信心间隔(CI ) :38.5%59.5%) 并且 49.2%(95% CI:38.3%59.2%) 分别地。58 (36 与 haploidentical 施主) 病人们经历了 allogeneic 在第一 CR 的造血的干细胞移植(allo-HSCT ) 。在在在正式就职以后的 CR1 的病人之中, 3 年的 OS 和 EFS 比在 without allo-HSCT 组在 allo-HSCT 组显著地更好(73.2% , 95% CI:58.3%83.5% 对 22.2% , 95% CI:8.7%39.6% 并且 66.5% , 95% CI:50.7%78.2% 对 16.1% , 95% CI:5.1%32.7% ,分别地) 。Multivariate 分析显示出那 allo-HSCT,主要分子的反应的成就独立地与有利 OS 或 EFS 被联系。在 allo-HSCT 队,有趣地,施主类型(haploidentical 对匹配的施主) 没在 EFS 或 OS 上有重要影响。所有这些结果建议加 CALLG2008 的那 imatinib 是一个有效协议为 Ph 积极所有。Haploidentical 施主能也是一个合理其他的有用施主水池。 | Yinjun Lou Yafang Ma Chenyin Li Sansan Suo Hongyan Tong Wenbin Qian Wenyuan Mai Haitao Meng Wenjuan Yu Liping Mao Juyin Wei Weilei Xu Jie Jin | 2017 | Frontiers of Medicine2017，11，2： | 3 |
| 4 | Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma: a single-center study in China显示文摘This study aimed to investigate the prevalence,clinical characteristics,and prognostic impact of 1p32.3 deletion in patients with newly diagnosed multiple myeloma (MM).A retrospective analysis was conducted on 411 patients with newly diagnosed MM;among which,270 received bortezomib-based therapies,and 141 received thalidomide-based therapies.Fluorescence in situ hybridization (FISH) was performed to detect six cytogenetic abnormalities,namely,del(1p32.3),gain(1q21),del(17p13),del(13q14),t(4;14),and t(11;14).Results showed that 8.3% of patients with MM were detected with del(1p32.3) and had significantly more bone marrow plasma cells (P =0.025),higher β2-microglobulin levels (P =0.036),and higher lactate dehydrogenase levels (P =0.042) than those without del(1p32.3).Univariate analysis showed that patients with del(1p32.3) under thalidomide-based therapies were strongly associated with short progression-free survival (PFS) (median PFS 11.6 vs.31.2 months,P =0.002) and overall survival (OS) (median OS 16.8 vs.45.9 months,P < 0.001).Multivariate analysis revealed that del(1p32.3) remained a powerful independent factor with worse PFS (P =0.006) and OS (P =0.016) for patients under thalidomide-based treatments.Patients with del(1 p32.3) under bortezomib-based treatments tended to have short PFS and OS.In conclusion,del(1p32.3) is associated with short PFS and OS in patients with MM who received thalidomide-or bortezomib-based treatments. | Huanping Wang Haitao Meng Jinghan Wang Yinjun Lou Yile Zhou Peipei Lin Fenglin Li Lin Liu Huan Xu Min Yang Jie Jin | 2020 | Frontiers of Medicine2020，14，3： | 2 |
| 5 | High efficacy of arsenic trioxide plus all-trans retinoic acid based induction and maintenance therapy in newly diagnosed acute promyelocytic leukemia显示文摘 | Yinjun Lou Wenbin Qian Haitao Meng Wenyuan Mai Hongyan Tong Yin Tong Jian Huang Jie Jin | 2013 | Leukemia Research2013，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员